HORMONE IN PROSTATIC FLUID AND PROSTATE CANCER RISK

目的是进行一项可行性和探索性的研究 年黑人和白人前列腺癌生化流行病学调查 在纽约市，选定的激素将同时在血清和 前列腺液。面谈将与病例和对照一起进行，以 收集前列腺癌已知和可疑危险因素的数据。这个 两个对照组，按医院、种族和年龄频率匹配，将 由既往无恶性肿瘤病史的患者组成 泌尿外科以外的外科服务，以及组织学上的患者 确诊为良性前列腺增生症。雌二醇雌酮水平， 睾酮、双氢睾酮和催乳素将通过 放射免疫分析。此外，催乳素将由大鼠NB2测定 淋巴瘤细胞生物测定、研究的分子形式及比较 可生物测定的催乳素水平和放射免疫测定的催乳素水平 病例和对照。前列腺液的激素检测结果将 与血清相关，与已知和疑似相关 各病例对照亚组的流行病学危险因素。 其目标是定义一种研究前列腺内分泌学的新方法。 并最终将此应用于深入的国际调查 不同性别黑人和白人人群的生化流行病学研究 前列腺癌风险水平。

The objective is to perform a feasibility and exploratory study of the biochemical epidemiology of prostate cancer in black and white patients in New York City in which selected hormones will be assayed in both serum and prostatic fluid. Interviews will be conducted with cases and controls to collect data on known and suspected risk factors for prostate cancer. The two control groups, frequency-matched by hospital, race and age, will consist of patients without prior history of malignancy from general surgical services other than urology, and patients with histologically confirmed benign prostatic hyperplasia. Levels of estradiol, estrone, testosterone, dihydrotestosterone and prolactin will be determined by radioimmunoassay. In addition, prolactin will be measured by the rat Nb2 lymphoma cell bioassay, the molecular forms studied, and comparisons made of the bioassayable and radioimmunoassayable levels of prolactin in both cases and controls. The results of hormone assays of prostatic fluid will be correlated with those of serum, and with known and suspected epidemiological risk factors in the various case-control subgroups. The goal is to define a new approach to the study of prostate endocrinology and, ultimately, to apply this to an in-depth international investigation of biochemical epidemiology in black and white populations of differing levels of prostate cancer risk.